When Is PUVA Therapy Recommended for Mycosis Fungoides?

PUVA combines a light-sensitising medicine with a carefully measured dose of ultraviolet A light. For mycosis fungoides, the aim is to reach abnormal skin cells in treated areas and reduce visible patches. A dermatologist or skin lymphoma team considers the stage, thickness, location and extent of the lesions before recommending it. PUVA is not automatically suitable for every person, and treatment planning also accounts for medicines, eye health, previous light exposure and the ability to attend repeated sessions.

Bring a complete list of medicines and tell the team about eye conditions, liver problems, light sensitivity, previous skin cancers and any difficulty standing in a treatment booth. Ask how the sensitising medicine is taken, how your eyes and skin must be protected, and how response will be checked. Attend sessions on the schedule provided and report unusual burning, blistering, marked redness or new symptoms rather than changing the dose yourself.

Contact the treating team promptly for severe redness, blistering, painful swelling, eye discomfort or visual changes after a session. Arrange an earlier review if lesions become thicker, ulcerated, rapidly more numerous, or associated with fever, persistent night sweating or unexplained weight loss. These changes need clinical assessment and should not be judged from photographs alone.

Ask whether your mycosis fungoides is skin-limited, what treatment goal is realistic, how long a trial may last, and which alternatives would be considered if PUVA is unsuitable or ineffective.